87 related articles for article (PubMed ID: 17106701)
1. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.
Sironi S; Picchio M; Landoni C; Galimberti S; Signorelli M; Bettinardi V; Perego P; Mangioni C; Messa C; Fazio F
Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):472-9. PubMed ID: 17106701
[TBL] [Abstract][Full Text] [Related]
2. What is the value of routine follow-up after diagnosis and treatment of cancer?
Rose PW; Watson E
Br J Gen Pract; 2009 Jul; 59(564):482-3. PubMed ID: 19566996
[No Abstract] [Full Text] [Related]
3. Recommendations for Follow-up Care for Gynecologic Cancer Survivors.
Elit L; Reade CJ
Obstet Gynecol; 2015 Dec; 126(6):1207-1214. PubMed ID: 26551194
[TBL] [Abstract][Full Text] [Related]
4. Range of Resection in Endometrial Cancer-Clinical Issues of Made-to-Measure Surgery.
Horala A; Szubert S; Nowak-Markwitz E
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791927
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET/MRI and 18F-FDG PET/CT for the Management of Gynecological Malignancies: A Comprehensive Review of the Literature.
Allahqoli L; Hakimi S; Laganà AS; Momenimovahed Z; Mazidimoradi A; Rahmani A; Fallahi A; Salehiniya H; Ghiasvand MM; Alkatout I
J Imaging; 2023 Oct; 9(10):. PubMed ID: 37888330
[TBL] [Abstract][Full Text] [Related]
6. A study on the clinical value of
Qi C; He S; Cai L; Zhang L; Ding H; Chen Y
Oncol Lett; 2021 Nov; 22(5):746. PubMed ID: 34539850
[TBL] [Abstract][Full Text] [Related]
7. Comparison of
Sawicki LM; Kirchner J; Grueneisen J; Ruhlmann V; Aktas B; Schaarschmidt BM; Forsting M; Herrmann K; Antoch G; Umutlu L
Eur J Nucl Med Mol Imaging; 2018 Apr; 45(4):622-629. PubMed ID: 29164299
[TBL] [Abstract][Full Text] [Related]
8. Complementary Roles of Squamous Cell Carcinoma Antigen and (18)F-FDG PET/CT in Suspected Recurrence of Cervical Squamous Cell Cancer.
Hu YY; Fan W; Zhang X; Liang PY; Lin XP; Zhang YR; Li YH
J Cancer; 2015; 6(3):287-91. PubMed ID: 25663947
[TBL] [Abstract][Full Text] [Related]
9. Role of 18F-FDG PET/CT in the carcinoma of the uterus: a review of literature.
Musto A; Grassetto G; Marzola MC; Chondrogiannis S; Maffione AM; Rampin L; Fuster D; Giammarile F; Colletti PM; Rubello D
Yonsei Med J; 2014 Nov; 55(6):1467-72. PubMed ID: 25323881
[TBL] [Abstract][Full Text] [Related]
10. [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results.
Beiderwellen K; Grueneisen J; Ruhlmann V; Buderath P; Aktas B; Heusch P; Kraff O; Forsting M; Lauenstein TC; Umutlu L
Eur J Nucl Med Mol Imaging; 2015 Jan; 42(1):56-65. PubMed ID: 25223420
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography alone, positron emission tomography-computed tomography and computed tomography in diagnosing recurrent cervical carcinoma: a systematic review and meta-analysis.
Xiao Y; Wei J; Zhang Y; Xiong W
Arch Med Sci; 2014 May; 10(2):222-31. PubMed ID: 24904653
[TBL] [Abstract][Full Text] [Related]
12. The role of FDG-PET/CT in gynaecological cancers.
Rockall AG; Cross S; Flanagan S; Moore E; Avril N
Cancer Imaging; 2012 Mar; 12(1):49-65. PubMed ID: 22391444
[TBL] [Abstract][Full Text] [Related]
13. Imaging of endometrial and cervical cancer.
Patel S; Liyanage SH; Sahdev A; Rockall AG; Reznek RH
Insights Imaging; 2010 Nov; 1(5-6):309-328. PubMed ID: 22347925
[TBL] [Abstract][Full Text] [Related]
14. Current therapy of patients with endometrial carcinoma. A critical review.
Marnitz S; Köhler C
Strahlenther Onkol; 2012 Jan; 188(1):12-20. PubMed ID: 22189438
[TBL] [Abstract][Full Text] [Related]
15. Detection of recurrence by 18F-FDG PET in patients with endometrial cancer showing no evidence of disease.
Ryu SY; Kim K; Kim Y; Park SI; Kim BJ; Kim MH; Choi SC; Lee ED; Lee KH; Kim BI
J Korean Med Sci; 2010 Jul; 25(7):1029-33. PubMed ID: 20592894
[TBL] [Abstract][Full Text] [Related]
16. Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence.
Kitajima K; Suzuki K; Nakamoto Y; Onishi Y; Sakamoto S; Senda M; Kita M; Sugimura K
Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1490-8. PubMed ID: 20386901
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?
Bilici A; Ustaalioglu BB; Seker M; Canpolat N; Tekinsoy B; Salepci T; Gumus M
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1259-69. PubMed ID: 20309683
[TBL] [Abstract][Full Text] [Related]
18. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma.
Pallardy A; Bodet-Milin C; Oudoux A; Campion L; Bourbouloux E; Sagan C; Ansquer C; Testard A; Resche I; Bridji B; Kraeber-Bodéré F; Rousseau C
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1270-8. PubMed ID: 20306032
[TBL] [Abstract][Full Text] [Related]
19. Novel imaging modalities in gynecologic cancer.
Brooks RA; Powell MA
Curr Oncol Rep; 2009 Nov; 11(6):466-72. PubMed ID: 19840524
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma.
Mittra E; El-Maghraby T; Rodriguez CA; Quon A; McDougall IR; Gambhir SS; Iagaru A
Eur J Nucl Med Mol Imaging; 2009 Dec; 36(12):1952-9. PubMed ID: 19585114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
